9. The relationship between controlling nutritional status index and clinical outcomes in patients with diffusive large B-cell lymphoma
Main Article Content
Abstract
This study aimed to evaluate the association between the CONUT index and clinical outcomes in patients with diffuse large B-cell lymphoma (DLBCL). A total of 112 patients diagnosed and treated for DLBCL at Military Hospital 103 between January 2019 and June 2025 were included. Patients with a CONUT score greater than 4 had a statistically higher rate of patients over 60 years old, Ann-Arbor stage III/IV disease, group B symptoms and R-IPI score ≥ 3 compared to those with a CONUT score of 4 or less (p < 0.05). The complete response rate was higher in the CONUT ≤ 4 group (75.0%) than in the CONUT > 4 group (56.8%) (p = 0.028). A CONUT score above 4 was associated with a 1.949-fold increased risk of disease progression and a 2.481-fold increased risk of death. Three-year progression-free survival (PFS) and overall survival (OS) rates were significantly lower in the CONUT > 4 group (37.7% and 56.8%, respectively) compared to the CONUT ≤ 4 group (57.6% and 77.9%) (p < 0.0001). The CONUT index is related to treatment response and may be an independent prognostic factor for progression-free survival and overall survival in DLBCL patients.
Article Details
Keywords
Diffuse large B-cell lymphoma, Controlling Nutritional Status (CONUT), Revised International Prognostic Index
References
3. Pileri SA, Tripodo C, Melle F, et al. Predictive and prognostic molecular factors in diffuse large B-cell lymphomas. Cells. 2021; 10(3): 1-15.
4. Zhou H, Chao W, Cui L, Li M, Zou Y, Yang M. Controlling Nutritional Status (CONUT) score as immune-nutritional predictor of outcomes in patients undergoing peritoneal dialysis. Clinical Nutrition. 2020; 39(8): 2564-2570.
5. Çağliyan Ga, Hacioğlu S, Koluman Bü, et al. Is CONUT score a prognostic index in patients with diffuse large cell lymphoma? Turkish Journal of Medical Sciences. 2021; 51(4): 2112-2119.
6. Baysal M, Bas V, Demirci U, et al. The utility of CONUT score in diffuse large B cell lymphoma patients. Nigerian Journal of Clinical Practice. 2021; 24(8): 1194-1199.
7. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. May 19 2016; 127(20): 2375-2390.
8. De Ulíbarri JI, González-Madroño A, de Villar NG, et al. CONUT: a tool for controlling nutritional status. First validation in a hospital population. Nutricion hospitalaria. 2005; 20(1): 38-45.
9. Cheson BD. Staging and response assessment in lymphomas: the new Lugano classification. Chinese clinical oncology. 2015; 4(1): 5-5.
10. Nagata A, Kanemasa Y, Sasaki Y, et al. Clinical impact of controlling nutritional status score on the prognosis of patients with diffuse large B-cell lymphoma. Hematological oncology. 2020; 38(3): 309-317.
11. Matsukawa T, Suto K, Kanaya M, et al. Validation and comparison of prognostic values of GNRI, PNI, and CONUT in newly diagnosed diffuse large B cell lymphoma. Annals of Hematology. 2020; 99(12): 2859-2868.
12. Go S-I, Choi B-H, Park MJ, et al. Prognostic impact of pretreatment skeletal muscle index and CONUT score in diffuse large B-cell lymphoma. BMC cancer. 2023; 23(1): 1071.
13. Yamamoto M, Saito H, Uejima C, et al. Prognostic value of combined tumor marker and controlling nutritional status (CONUT) score in colorectal cancer patients. Yonago Acta Medica. 2019; 62(1): 124-130.
14. Oh JS, Park DJ, Byeon K-H, et al. Decrease of preoperative serum albumin-to-globulin ratio as a prognostic indicator after radical cystectomy in patients with urothelial bladder cancer: Albumin-to-globulin ratio and bladder cancer. Urology Journal. 2021; 18(01): 66-73.
15. Pepedil-Tanrikulu F, Buyukkurt N, Korur A, et al. Significance of Lymphocyte Count, Monocyte Count, and Lymphocyte-To-Monocyte Ratio in Predicting Molecular Response in Patients with Chronic Myeloid Leukemia: a Single-Centre Experience. Clinical Laboratory. 2020; 66(3): 319.